A. Gallus

Publications261
h-index61
Citations23,137
Highly Influential Citations651
Claim Author Page
Author pages are created from data sourced from our academic publisher partnerships and public sources.

Recommended Authors

  • A. Turpie
  • 430 Publications • 41,416 Citations
  • J. Hirsh
  • 591 Publications • 58,310 Citations
  • M. Crowther
  • 524 Publications • 37,265 Citations
  • G. Raskob
  • 277 Publications • 33,544 Citations
  • Publications
  • Influence
Oral anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.
BACKGROUND The objective of this article is to summarize the published literature concerning the pharmacokinetics and pharmacodynamics of oral anticoagulant drugs that are currently available for… Expand
  • 1,124
  • 67
  • PDF
Oral rivaroxaban for symptomatic venous thromboembolism.
BACKGROUND Rivaroxaban, an oral factor Xa inhibitor, may provide a simple, fixed-dose regimen for treating acute deep-vein thrombosis (DVT) and for continued treatment, without the need for… Expand
  • 1,982
  • 66
  • PDF
Oral apixaban for the treatment of acute venous thromboembolism.
BACKGROUND Apixaban, an oral factor Xa inhibitor administered in fixed doses, may simplify the treatment of venous thromboembolism. METHODS In this randomized, double-blind study, we compared… Expand
  • 1,536
  • 63
  • PDF
Apixaban for extended treatment of venous thromboembolism.
BACKGROUND Apixaban, an oral factor Xa inhibitor that can be administered in a simple, fixed-dose regimen, may be an option for the extended treatment of venous thromboembolism. METHODS In this… Expand
  • 932
  • 43
  • PDF
Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial
BACKGROUND Low-molecular-weight heparins such as enoxaparin are preferred for prevention of venous thromboembolism after major joint replacement. Apixaban, an orally active factor Xa inhibitor, might… Expand
  • 684
  • 34
  • PDF
Apixaban or enoxaparin for thromboprophylaxis after knee replacement.
BACKGROUND The optimal strategy for thromboprophylaxis after major joint replacement has not been established. Low-molecular-weight heparins such as enoxaparin predominantly target factor Xa but to… Expand
  • 642
  • 28
Efficacy and safety of fondaparinux for the prevention of venous thromboembolism in older acute medical patients: randomised placebo controlled trial
Abstract Objective To determine the efficacy and safety of the anticoagulant fondaparinux in older acute medical inpatients at moderate to high risk of venous thromboembolism. Design Double blind… Expand
  • 729
  • 26
  • PDF
Apixaban versus enoxaparin for thromboprophylaxis after hip replacement.
BACKGROUND There are various regimens for thromboprophylaxis after hip replacement. Low-molecular-weight heparins such as enoxaparin predominantly inhibit factor Xa but also inhibit thrombin to some… Expand
  • 658
  • 25
Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. The Tasman Study…
BACKGROUND An intravenous course of standard (unfractionated) heparin with the dose adjusted to prolong the activated partial-thromboplastin time to a desired length is the standard initial… Expand
  • 1,058
  • 17
Oral rivaroxaban for the treatment of symptomatic pulmonary embolism.
BACKGROUND A fixed-dose regimen of rivaroxaban, an oral factor Xa inhibitor, has been shown to be as effective as standard anticoagulant therapy for the treatment of deep-vein thrombosis, without the… Expand
  • 1,581
  • 16
  • PDF
...
1
2
3
4
5
...